ArticleProstate international2025
Article in Prostate international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Florastamin Uptake on PSMA PET/CT as an Imaging Biomarker of Tumor Aggressiveness in Prostate Cancer.Diagnostics (Basel, Switzerland) · 2026Article
- Utilization of prostate-specific membrane antigen positron emission tomography in Australia following government subsidization: Trends in primary staging and biochemical recurrence.Prostate international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Research on prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and pending Food and Drug Administration (FDA) approval are predominantly aimed at biochemical recurrence rather than presurgical staging. Studies on the latter indication have almost exclusively investigated biopsy-proven cancers. We herein present the first-in-man clinical evaluation of a novel Methods: We recruited twenty men with prostate-specific antigen (PSA) levels between 3 (the threshold for biopsy) and 20 n/mL. A dose of 267-370 MBq (8-10 mCi) Results: Twenty patients, who had a median PSA of 8.02 ng/mL (range 3.24-18.6), were enrolled in this study. Twelve patients were biopsy-proven with prostate cancer, of which four were low-risk and eight were intermediate risk. PET/CT visual analysis identified abnormal Conclusion: Clinical trial number: (CRIS) KCT0004609.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.